摘要
Although diffuse large B-cell lymphoma(DLBCL)is considered as a curable disease after standard immunochemotherapy,approximately30%of patients would succumb to short survival.To date,clinical presentations and gene expressions have been used to identify these high-risk patients.
基金
This work was supported by Zhejiang Provincial Natural Science Foundation of China(No.LY19H080009,and LY20H080008)
Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province(China)(No.JBZX-201904)
This study is also supported by the major projects of Zhejiang Provincial Department of Science and Technology 491010+J3210NZJ(China)
the Research Project of Jinan Microecological Biomedicine Shandong Laboratory,Jinan,China.
